PKG plus routine assessment is associated with lower total costs compared to routine assessment (£141,950 versus £159,312) and improved quality adjusted life years (7.88 versus 7.61), resulting in an incremental cost-effectiveness ratio of -£64,978.99 and a net monetary benefit of £22,706.37 using a £20,000 threshold.

Management of PD involves monitoring and evaluation of symptoms to assess disease progression and ensure appropriate treatment choice. Adding the PKG to standard monitoring allows for improved and objective identification of PD motor symptoms which can be used in clinical decision making to improve patient outcomes.

More here: PubMed abstract